Related Experiment Video
Updated: Sep 30, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Smad4 and p53 synergize in suppressing autochthonous intestinal cancer
Jun Won Park1,2, Min-Jung Seo1, Kye Soo Cho1,3
1National Cancer Center, Goyang, Republic of Korea.
Background:
Smad4 and p53 mutations are the most common mutations in human colorectal cancers (CRCs). We evaluated whether and how they are synergistic in intestinal carcinogenesis using novel autochthonous mouse models.
Method:
To recapitulate human CRCs, we generated Villin-Cre;Smad4F / F ;Trp53F / F mice. We then compared the intestinal phenotype of Villin-Cre;Smad4F / F ;Trp53F / F mice (n = 40) with Villin-Cre;Smad4F / F (n = 30) and Villin-Cre;Trp53F / F mice (n = 45).
Results:
Twenty-week-old Villin-Cre;Smad4F / F ;Trp53F / F mice displayed spontaneous highly proliferative intestinal tumors, and 85% of mice developed adenocarcinomas. p21 was downregulated in the intestinal mucosa in Villin-Cre;Smad4F / F ;Trp53F / F mice than in Villin-Cre;Smad4F / F and Villin-Cre;Trp53F / F mice. Villin-Cre;Smad4F / F ;Trp53F / F mice displayed multistep intestinal tumorigenesis and Wnt activation. Long-term CWP232291 (small-molecule Wnt inhibitor) treatment of Villin-Cre;Smad4F / F ;Trp53F / F mice suppressed intestinal tumorigenesis and progression. CWP232291 treatment downregulated cancer stem cell (CSC) tumor markers including CD133, Lgr-5, and Sca-1. CWP232291 treatment reduced the CSC frequency. Small-molecule Wnt inhibitors reduced intestinal CSC populations and inhibited their growth, along with Bcl-XL downregulation. Furthermore, BH3I-1, a Bcl-XL antagonist, increasingly inhibited intestinal CSCs than bulk tumor cells.
Conclusion:
Smad4 loss and p53 loss are synergistic in autochthonous intestinal carcinogenesis, by downregulating p21 and activating Wnt/β-catenin pathway.
Insights
Smad4 and p53 mutations synergistically drive intestinal cancer by downregulating p21 and activating the Wnt pathway. Targeting Wnt signaling with inhibitors like CWP232291 suppressed tumor growth and cancer stem cells.
Area of Science:
- Oncology
- Gastroenterology
- Molecular Biology
Background:
- Colorectal cancers (CRCs) frequently harbor mutations in Smad4 and p53.
- The synergistic role of these common mutations in intestinal carcinogenesis remains incompletely understood.
Purpose of the Study:
- To investigate the synergistic effects of Smad4 and p53 loss in intestinal carcinogenesis.
- To elucidate the molecular mechanisms underlying this synergy.
Main Methods:
- Generation of novel autochthonous mouse models (Villin-Cre;Smad4F/F;Trp53F/F) to recapitulate human CRCs.
- Comparative analysis of intestinal phenotypes and molecular markers between different genetically modified mouse groups.
- Treatment with a small-molecule Wnt inhibitor (CWP232291) and a Bcl-XL antagonist (BH3I-1) to assess therapeutic efficacy.
Main Results:
- Villin-Cre;Smad4F/F;Trp53F/F mice developed spontaneous, highly proliferative intestinal tumors and adenocarcinomas.
- Loss of Smad4 and p53 led to p21 downregulation and Wnt/β-catenin pathway activation.
- Wnt inhibition suppressed tumor progression, reduced cancer stem cell (CSC) markers (CD133, Lgr-5, Sca-1), and decreased CSC frequency.
- Bcl-XL antagonism further inhibited intestinal CSCs.
Conclusions:
- Smad4 and p53 loss act synergistically in driving intestinal carcinogenesis.
- The synergistic effect involves p21 downregulation and Wnt/β-catenin pathway activation.
- Targeting the Wnt pathway and Bcl-XL shows therapeutic potential against Smad4/p53-mutated colorectal cancers.
Related Concept Videos
Abnormal Proliferation
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
DNA Damage can Stall the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Intrinsic Apoptotic Pathway
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...

